Phaseline

Targets › PRKC

PRKC: drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Oncology; next expected readout Apr 2027.

Open in Phaseline: the race on PRKC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IDEAYA BiosciencesDarovasertib
Protein Kinase C (PKC) inhibitor
PRKCPhase 3Uveal MelanomaApr 2027

Conditions

Uveal Melanoma (3)

Modalities

small molecule (1)

Companies

IDEAYA Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.